^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ralimetinib (LY 2228820)

    i
    Associations
    News

    Trials

    Company:
    Eli Lilly
    Drug class:
    MAPK inhibitor, p38 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma (GLYRad) (NCT02364206)
    Phase 1/2
    Centre Jean Perrin
    Completed
    Last update posted :
    08/14/2019
    Initiation :
    06/08/2015
    Primary completion :
    08/01/2019
    Completion :
    08/01/2019
    PTEN • IDH1
    |
    temozolomide • ralimetinib (LY 2228820)
    A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer (NCT02860780)
    Phase 1
    Eli Lilly and Company
    Completed
    Last update posted :
    12/14/2018
    Initiation :
    08/10/2016
    Primary completion :
    05/15/2017
    Completion :
    05/15/2017
    KRAS • BRAF
    |
    KRAS mutation • BRAF mutation
    |
    prexasertib (ACR-368) • ralimetinib (LY 2228820)